newsfilter
← Latest News
PR Newswire·

Mirati To Present Updated Clinical Data at ESMO Congress 2023

Late-Breaking KRYSTAL-7 data demonstrates compelling efficacy and safety of adagrasib in combination with pembrolizumab in 1L NSCLC Data follows recent inclusion of the adagrasib in combination with an EGFR inhibitor